[
    [
        {
            "time": "2018-08-31",
            "original_text": "Why DexCom Soared 51.8% in August",
            "features": {
                "keywords": [
                    "DexCom",
                    "Soared",
                    "51.8%",
                    "August"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why DexCom Soared 51.8% in August",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 10,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Blood Disorder",
                    "Cablivi",
                    "Approval",
                    "Europe"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-31",
            "original_text": "Examining Eli Lilly’s Oncology Products’ Q2 2018 Performances",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Oncology",
                    "Q2",
                    "2018",
                    "Performances"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "oncology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Examining Eli Lilly’s Oncology Products’ Q2 2018 Performances",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-09-14",
            "original_text": "Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe",
            "features": {
                "keywords": [
                    "Sanofi",
                    "Blood Disorder",
                    "Cablivi",
                    "Approval",
                    "Europe"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-31",
            "original_text": "Assessing Eli Lilly’s Human Pharmaceutical Segment in Q2 2018",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Human Pharmaceutical",
                    "Segment",
                    "Q2",
                    "2018"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Assessing Eli Lilly’s Human Pharmaceutical Segment in Q2 2018",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]